Microbiol Spectr. 2025 Oct 30. e0031425
Beverly Egyir,
Rhodalyn Tagoe,
Nicholas T K D Dayie,
Jeannette Bentum,
Christian Owusu-Nyantakyi,
Daniel Kwaku Baka,
Blessing Kofi Adu Tabi,
Appiah-Korang Labi,
Noah Obeng-Nkrumah,
Eric Behene,
Salamatu Ibrahim,
Felicia Owusu,
Francis Adjei,
Bright Agbodzi,
Selassie Kumordjie,
Julian Adinkrah,
Awuiwenyuei Annankra,
Isaac Yeboah,
William Asiedu,
Michael Adufutse,
Philip Asare Annor Nyinaku,
Edward Owusu Nyarko,
Edward Asumanu,
Harriet Manu,
Naiki Attram,
Robert D Hontz,
Anne Fox,
Hugo Miranda Quijada,
Terrel Sanders.
Surgical site infections (SSIs) caused by Pseudomonas aeruginosa pose significant challenges in healthcare, particularly in low and middle-income countries (LMICs). Understanding the genomic characteristics and antimicrobial resistance profiles of P. aeruginosa isolates is crucial for informing appropriate treatment and guiding infection prevention and control strategies. P. aeruginosa isolates recovered from SSIs were analyzed using whole-genome sequencing and antimicrobial susceptibility testing. The isolates were identified using matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-ToF MS) system, and their antibiotic susceptibilities were determined using the Kirby-Bauer disk diffusion method and interpreted with Clinical and Laboratory Standards Institute guidelines. Whole-genome sequencing was performed using the Illumina MiSeq platform, and sequence data were analyzed using free online bioinformatics tools, including CARD-RGI, ResFinder, PAst, VFDB, and MLST. Between July 2018 and September 2023, 563 patients were enrolled in a surgical site infection study, which led to the recovery of 82 P. aeruginosa isolates. The isolates were resistant to ciprofloxacin (n = 23, 28.05%), gentamicin (n = 20, 24.39%), piperacillin-tazobactam (n = 13, 15.85%), cefepime (n = 12, 14.63%), ceftazidime (n = 12, 14.63%), meropenem (n = 10, 12.20%), and amikacin (n = 8, 9.76%). Multidrug resistance was noted in 10 isolates (12.20%), with three isolates resistant to all antibiotics tested (n = 3, 3.7%). Sequence data revealed international high-risk clones: ST308 and ST773 (n = 5 each, 6.10%), ST244 (n = 4, 4.88%), ST446, ST357, and ST654 (n = 2 each, 2.44%), and ST235 (n = 1, 1.41%). Newly identified sequence types ST4287, ST4288, ST4289, ST4521, ST4522, ST4523, and ST4524 were also detected. Serotype O11 (n = 28, 34.15%) was the most prevalent, followed by O5, O6, and O4. Key virulence genes, such as algD, lasB, exoS, plcH, toxA, and plcN, were also detected. The identification of both high-risk and novel clones, coupled with diverse resistance and virulence factors, underscores the need for continuous surveillance of circulating strains. Employing advanced technologies, such as whole-genome sequencing, is essential for guiding infection control and treatment strategies in Ghanaian hospital settings.IMPORTANCESurgical site infections (SSIs) caused by multidrug-resistant Pseudomonas aeruginosa are a major challenge to patient care, particularly in low-resource settings. This study reveals extensive genomic diversity, antimicrobial resistance, and virulence profiles among P. aeruginosa isolates from SSIs in Ghanaian hospitals. The detection of globally recognized high-risk clones ST235, ST308, and ST773, alongside several novel sequence types, suggests ongoing genomic evolution and the potential for regional dissemination. The presence of resistance to last-line antibiotics and key virulence factors highlights the therapeutic and public health challenges in low and middle-income countries. These findings underscore the urgent need for genomic surveillance, strengthened infection prevention and control, and targeted antimicrobial stewardship programs to inform treatment strategies and health policies across Ghana and the broader African region.
Keywords: Pseudomonas aeruginosa; antimicrobial resistance; low-and middle-income countries; public health surveillance; whole-genome sequencing